These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 11298704

  • 1. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Apr; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Apr; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 5. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 6. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A, Rogowski W.
    BMC Health Serv Res; 2009 Jul 10; 9():115. PubMed ID: 19591680
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May 10; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 8. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 May 10; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 9. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb 10; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Feb 10; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 11. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Feb 10; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM, Waycaster CR, Motley TA.
    Wound Repair Regen; 2015 Feb 10; 23(3):353-60. PubMed ID: 25810233
    [Abstract] [Full Text] [Related]

  • 13. Use of Regranex gel for diabetic foot ulcers.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998 Feb 10; 38(5):628-30. PubMed ID: 9782698
    [No Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
    Waycaster CR, Gilligan AM, Motley TA.
    J Am Podiatr Med Assoc; 2016 Jul 10; 106(4):273-82. PubMed ID: 27049838
    [Abstract] [Full Text] [Related]

  • 15. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N, Maltezos E.
    Drug Saf; 2010 Jun 01; 33(6):455-61. PubMed ID: 20486728
    [Abstract] [Full Text] [Related]

  • 16. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS, Robson MC, Smiell JM, Perry BH.
    Wound Repair Regen; 1999 Jun 01; 7(3):141-7. PubMed ID: 10417749
    [Abstract] [Full Text] [Related]

  • 17. Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers: A Health Technology Assessment.
    Health Quality Ontario.
    Ont Health Technol Assess Ser; 2017 Jun 01; 17(5):1-142. PubMed ID: 28572866
    [Abstract] [Full Text] [Related]

  • 18. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV.
    Adv Skin Wound Care; 2000 Jun 01; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [Abstract] [Full Text] [Related]

  • 19. The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers.
    Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A, Wasem J.
    GMS Health Technol Assess; 2010 Sep 01; 6():Doc12. PubMed ID: 21289885
    [Abstract] [Full Text] [Related]

  • 20. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colín S, Paz-Janeiro JL, Alvarado-Ruiz R, García-Salazar R.
    Adv Ther; 2000 Sep 01; 17(4):184-9. PubMed ID: 11185057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.